4.63MMarket Cap-354P/E (TTM)
0.5806High0.2950Low14.02MVolume0.3039Open0.3040Pre Close7.53MTurnover294.81%Turnover RatioLossP/E (Static)8.65MShares1.140052wk High2.10P/B2.55MFloat Cap0.291452wk Low--Dividend TTM4.76MShs Float115.2000Historical High--Div YieldTTM93.95%Amplitude0.2914Historical Low0.5360Avg Price1Lot Size
Exicure Stock Forum
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.
$DMK Pharmaceuticals(DMK.US)$ $NanoString Technologies(NSTG.US)$ $Phunware(PHUN.US)$ $Exicure(XCUR.US)$ $Gorilla Technology(GRRR.US)$
📊⚡️📊
$Gorilla Technology(GRRR.US)$ $Exicure(XCUR.US)$ $Volcon(VLCN.US)$ $Biofrontera(BFRI.US)$ $Yield10 Bioscience(YTEN.US)$ $Atara Biotherapeutics(ATRA.US)$
📊⚡️📊
5 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE
No comment yet